Aquestive Therapeutics (AQST) Q4 2024: Anaphylm NDA Filing Initiates Path to 2026 Launch Amid Commercial and Clinical Expansion
Aquestive Therapeutics initiated the NDA filing process for Anaphylm, a novel epinephrine sublingual film, marking a pivotal milestone toward its anticipated 2026 launch. While revenues declined slightly in Q4 due to prior-year milestone recognition and manufacturing shifts, the company is intensifying commercial preparations and advancing its pipeline, positioning for growth beyond legacy contract manufacturing. The 2025 outlook reflects significant pre-commercial investment, with key regulatory and clinical catalysts ahead.
Summary
- Regulatory Milestone Achieved: NDA submission for Anaphylm commenced, targeting FDA acceptance in Q2 2025.
- Commercial Readiness Advancing: In-house market access and medical affairs efforts scaled to support launch and payer engagement.
- Pipeline Progress: AQST-108 topical gel Phase 2a trial set for Q2 2025, expanding dermatology franchise opportunities.
Business Overview
Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing innovative drug delivery technologies, primarily in the specialty pharmaceutical space. The company generates revenue through manufacturing and supply agreements, license and royalty income, and co-development fees. Its major segments include contract manufacturing for licensed products, royalty income from approved drugs such as Libervant® (diazepam) Buccal Film, and its proprietary product pipeline with key candidates like Anaphylm™ epinephrine sublingual film and AQST-108 topical gel.
Performance Analysis
In the fourth quarter of 2024, Aquestive reported a 10 percent decline in total revenues to $11.9 million, driven by a $1 million reduction in license and royalty revenue compared to the prior year, reflecting the absence of milestone payments recognized in 2023. Manufacturing and supply revenues fell modestly to $10.7 million, impacted by lower Suboxone® volumes partially offset by increased Ondif® revenues. Full-year 2024 revenues grew 14 percent to $57.6 million, primarily due to deferred revenue recognition from terminated licensing agreements and increased co-development fees, though excluding these one-time items, manufacturing revenues declined by approximately 9 percent year-over-year.
R&D expenses rose significantly to $4.9 million in Q4 and $20.3 million for the full year, reflecting intensified clinical activity on Anaphylm and AQST-108. SG&A expenses increased to $16 million in Q4 and $50.2 million for the year, driven by commercial buildout for Libervant and pre-launch activities for Anaphylm, including severance and legal costs. The net loss widened to $17.1 million in Q4 and $44.1 million for the year, with non-GAAP adjusted EBITDA loss more than doubling, highlighting the investment phase ahead of anticipated product approvals and launches.
- Revenue Mix Shift: Declines in legacy manufacturing offset by growing license and co-development fees.
- Investment Ramp-Up: Elevated R&D and SG&A reflect strategic prioritization of pipeline advancement and commercialization.
- Cash Position Strengthened: Pro forma cash of approximately $93 million post-ATM raise supports upcoming milestones.
This financial profile underscores Aquestive’s transition from a contract manufacturing-reliant model toward a commercial-stage specialty pharma entity with proprietary products poised to drive future growth.
Executive Commentary
"We have begun the filing process with the FDA for approval of our Anaphylm epinephrine sublingual film application, expecting NDA acceptance by June and a potential launch in Q1 2026. This is a major milestone years in the making, reflecting our commitment to delivering a non-device, easy-to-carry epinephrine option that we believe patients will prefer."
Dan Barber, Chief Executive Officer
"Our 2025 guidance incorporates significant pre-commercial spending for Anaphylm, costs related to the NDA submission, completion of pediatric clinical trials, and the initiation of AQST-108 Phase 2a studies. We remain focused on advancing these programs while continuing to commercialize Libervant for young epilepsy patients."
Ernie Toth, Chief Financial Officer
Strategic Positioning
1. Anaphylm NDA Filing and Regulatory Strategy
Aquestive has completed adult clinical trials and received positive FDA pre-NDA feedback, now progressing with pediatric data inclusion. The company anticipates potential FDA advisory committee engagement in the second half of 2025 and has engaged external expertise to prepare comprehensively. This regulatory approach aims to position Anaphylm as a preferred, fast-acting, non-invasive epinephrine alternative, potentially reshaping emergency allergy treatment.
2. Commercial Infrastructure and Market Access Development
Pre-launch activities include hiring in-house market access leadership and expanding medical affairs presence through publications and conferences. The company plans to launch Anaphylm with an approximate 100-person sales force post-approval, targeting allergists, pediatricians, and primary care providers. Partnership discussions are ongoing but Aquestive remains prepared to commercialize independently, emphasizing patient access and broad market penetration.
3. Pipeline Expansion with AQST-108
Building on Anaphylm, AQST-108, a topical epinephrine gel targeting alopecia areata, is on track to enter Phase 2a trials in Q2 2025. Given the large addressable patient population and unmet needs with current JAK inhibitor therapies, this program represents a meaningful growth opportunity leveraging Aquestive’s proprietary Adrenaverse™ platform.
4. Libervant Commercial and Legal Challenges
While Libervant secured FDA approval and orphan drug exclusivity for ages two to five, a recent court ruling challenged this exclusivity, prompting an appeal. Aquestive remains committed to maintaining patient access and continuing commercialization for this vulnerable population, with plans to expand label indications over the next two years.
5. International Expansion and Partnerships
Following U.S. regulatory progress, Aquestive is preparing submissions for Anaphylm in the EU, UK, and Canada, exploring ex-U.S. partnerships to extend commercial reach. This dual approach balances direct U.S. commercialization with strategic collaborations abroad to maximize global patient access and revenue potential.
Key Considerations
Aquestive is navigating a critical inflection point transitioning from a manufacturing-focused entity to a commercial-stage specialty pharmaceutical company with proprietary products. Key considerations include:
- Regulatory Execution: Successful NDA acceptance and potential advisory committee outcomes will be pivotal for Anaphylm’s approval timeline and label scope.
- Commercial Investment Timing: Pre-commercial spending is front-loaded in 2025, with scalability depending on launch timing and possible partnerships.
- Market Adoption Dynamics: Physician preference surveys suggest strong interest in oral film delivery, but competitive dynamics with existing injectors and nasal sprays require ongoing education and access efforts.
- Legal and Access Risks: The Libervant court ruling introduces uncertainty in a key revenue stream, necessitating legal appeals and strategic responses.
- Pipeline Development: AQST-108’s clinical progress and eventual approval could diversify revenue streams and leverage platform technology.
Risks
Risks include potential delays or adverse outcomes in the FDA review process, including the uncertain advisory committee decision. The legal challenge to Libervant’s orphan drug exclusivity could materially impact revenue if unresolved. Market adoption of Anaphylm depends on payer coverage and physician acceptance amid competitive alternatives. Clinical trial recruitment and execution for AQST-108 carry inherent uncertainties. Financially, elevated R&D and SG&A spending pressure near-term profitability and cash flow.
Forward Outlook
For 2025, Aquestive guided total revenues between $47 million and $56 million and a non-GAAP adjusted EBITDA loss ranging from $46 million to $53 million. This outlook includes continued commercialization of Libervant for ages two to five, anticipated erosion in Suboxone demand, and significant pre-commercial investment for Anaphylm. Management expects to complete the Anaphylm NDA acceptance process by mid-year, initiate AQST-108 Phase 2a trials in Q2, and advance international regulatory filings. The company plans to expand commercial infrastructure in the second half of 2025 in preparation for a potential early 2026 Anaphylm launch.
Takeaways
Aquestive is strategically repositioning itself with the imminent Anaphylm NDA filing marking a transformative step toward commercial launch and proprietary product leadership. Elevated clinical and commercial investments reflect confidence in the product’s differentiated profile and market potential. However, legal uncertainties around Libervant and the need for successful regulatory navigation present material execution risks. Investors should monitor upcoming FDA milestones, partnership developments, and early commercial traction indicators as key inflection points.
- Transitioning Business Model: From contract manufacturing dependence toward proprietary product commercialization with Anaphylm and AQST-108.
- Regulatory and Commercial Execution: NDA acceptance and advisory committee outcomes will critically shape 2026 launch prospects and market access.
- Legal and Competitive Environment: Ongoing Libervant litigation and competitive epinephrine product launches underscore the need for robust market differentiation and payer engagement.
Conclusion
Aquestive’s Q4 2024 results reflect a company in active transformation, marked by a significant regulatory milestone with the Anaphylm NDA submission and robust pipeline progression. While near-term financials show increased losses due to investment ramp-up, the company is positioning for long-term growth through innovative product launches and international expansion. Execution on regulatory, commercial, and legal fronts will be critical to realizing this potential.
Industry Read-Through
Aquestive’s progress with a needle-free epinephrine delivery system highlights a broader industry trend toward patient-centric, non-invasive drug delivery technologies that aim to improve adherence and outcomes in acute care settings. The competitive landscape in epinephrine products is evolving with new formulations challenging entrenched autoinjectors. Payer engagement and real-world evidence will increasingly influence market dynamics. Additionally, legal disputes over orphan drug exclusivity rights, as seen with Libervant, may signal heightened scrutiny and litigation risks across specialty pharma, affecting product lifecycle management and revenue predictability.